

Supplementary Material




Fig. S1 Kaplan–Meier estimates of the patient population for (A) OS comparing ECOG 0 (red; 14.9 months, CI 95% 13.4-22.6) vs. ECOG >0 (turquoise; 3.9 months, CI 95% 1.8-15.6; p<0.001), and (B) OS comparing LDH not elevated (red, 23.7 months, CI 95% 13.4-NR) vs. LDH elevated (turquoise; 11.3 months, CI 95% 7.5-15.4; p=0.0032).




Fig. S2 Kaplan–Meier estimates of the patient population for (A) PFS of the entire population with 2.7 months (CI 95% 2.4-3.0), and (B) PFS comparing cohort A (red; 3 months, CI 95% 2.4-4) vs. B (turquoise; 2.5 months,




Fig. S3 Kaplan–Meier estimates of the patient population for (A) OS comparing SIRT (n=53, turquoise; median OS 23.7 months, CI 95% 17.8-NR) vs. other LDT (LDT without SIRT; n=25, red; 13.4 months, CI 95% 8.8-NR; p=0.63), (B) OS comparing cohort A1 (LDT before ICB, n=23; red; median OS 18.2 months, CI 95% 13.4-NR) vs. cohort A2 (LDT concurrent with ICB, n=14, green; 26.0 months, CI 95% 26.0-NR) vs. cohort A3 (LDT after ICB, n=19, turquoise; 23.7 months, CI 95% 15.4-NR); p=0.038, (C) PFS comparing SIRT (n=36, turquoise; median PFS 3.5 months, CI 95% 2.3-5.5) vs. other LDT (LDT without SIRT; n=13, red; 2.6 months, CI 95% 2.4-5.3; p=0.15), and (D) PFS comparing cohort A1 (LDT before ICB, n=14; red; median PFS 2.4 months, CI 95% 1.9-11.1) vs. cohort A2 (LDT concurrent with ICB, n=9, green; 3.5 months, CI 95% 2.5-NR) vs. cohort A3 (LDT after ICB, n=13, turquoise; 3.5 months, CI 95% 2.0-NR); p=0.98.